Aspergillosis clinical trials at UCSF
1 research study open to eligible people
Aspergillosis is an infection from a fungus that affects the lungs. UCSF is comparing a new drug, olorofim, to a standard treatment to see which is more effective. These trials are essential for improving patient care.
Showing trials for
Olorofim Aspergillus Infection Study
open to eligible people ages 18 years and up
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
San Francisco, California and other locations
Last updated: